Our Pricing

Wegovy 0.25 Click Chart: Complete Dosing Guide for Your Starting Dose

Published: 11 September 2026

The wegovy 0.25 click chart provides essential guidance for patients beginning their weight loss journey with Wegovy's lowest starting dose. Understanding how to correctly dial 0.25 mg using the pen's click mechanism ensures accurate dosing and optimal treatment outcomes. At Cured Pharmacy, our UK-registered clinical team supports patients through every stage of Wegovy treatment, from initial 0.25 mg dosing through to maintenance therapy.

Understanding the Wegovy 0.25 Click Chart and Pen Mechanism

The wegovy 0.25 click chart serves as a visual reference for patients using the pre-filled injection device to administer their starting dose. Each Wegovy pen is calibrated to deliver precise doses through a click-based dial system, where each audible and tactile click represents a specific dose increment [1]. For the 0.25 mg starting dose, patients must dial the pen to the first marked position, which corresponds to one complete click from the zero position.

Wegovy pens are designed with dose markers clearly visible in the dose window, eliminating guesswork during administration. The 0.25 mg dose appears as the first dosing option on the pen dial, making it straightforward for treatment-naïve patients to identify. This starting dose is maintained for four weeks during the initial titration phase, allowing the body to gradually adjust to semaglutide before dose escalation [2]. Clinical trials demonstrated that this gradual approach significantly reduces gastrointestinal side effects compared to starting at higher doses.

Step-by-Step Wegovy 0.25 Click Chart Instructions for First-Time Users

To use the wegovy 0.25 click chart effectively, begin by removing the pen cap and checking the medication window to ensure the solution is clear and colourless. Turn the dose selector dial clockwise until you hear and feel one distinct click, which positions the pen at the 0.25 mg marking visible in the dose window. The pen will not allow you to select a dose higher than what remains in the cartridge, providing an additional safety mechanism.

Once the 0.25 mg dose is dialled, insert a new needle tip onto the pen and perform the flow check as outlined in the patient information leaflet. Select your injection site—typically the abdomen, thigh, or upper arm—and insert the needle at a 90-degree angle. Press and hold the dose button until the dose counter returns to zero, then continue holding for an additional six seconds to ensure complete medication delivery [3]. This technique, validated in clinical practice, ensures patients receive the full prescribed dose without medication leakage.

Common Mistakes When Using the 0.25 mg Click Chart

Patients occasionally dial past the 0.25 mg marking or fail to hold the injection button for the required duration. The wegovy 0.25 click chart emphasises counting clicks carefully—one click equals 0.25 mg, two clicks equal 0.5 mg, and so forth. If you accidentally dial past your intended dose, simply turn the selector back to the correct position without wasting medication. Never attempt to adjust the dose while the needle is inserted, as this can cause inaccurate dosing and potential tissue damage.

Wegovy 0.25 Click Chart Dosing Schedule and Titration Timeline

The wegovy 0.25 click chart represents only the first stage of a structured dose escalation protocol designed to optimise weight loss whilst minimising adverse effects. Patients remain on the 0.25 mg dose for four consecutive weeks (four injections total, administered once weekly), after which the dose increases to 0.5 mg for another four weeks [4]. This gradual titration continues through 1.0 mg, 1.7 mg, and finally reaches the maintenance dose of 2.4 mg at week 17.

Clinical data from the STEP trials showed that patients following this titration schedule achieved an average weight loss of 15% of initial body weight over 68 weeks, with the most significant reductions occurring after reaching the 2.4 mg maintenance dose [5]. However, the initial 0.25 mg phase remains crucial for treatment adherence, as patients who experience manageable side effects during this period are significantly more likely to continue treatment through to therapeutic doses. At Cured Pharmacy, our prescribers provide personalised titration guidance, adjusting schedules when necessary based on individual tolerance and response.

Wegovy 0.25 Click Chart Safety Considerations and Side Effect Management

Even at the 0.25 mg starting dose indicated on the wegovy 0.25 click chart, patients may experience mild gastrointestinal effects including nausea, diarrhoea, or constipation. These effects typically diminish within the first few weeks as the body adapts to semaglutide [6]. To minimise discomfort, our clinical team recommends eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated throughout treatment.

Serious adverse effects are rare at the 0.25 mg dose but require immediate medical attention if they occur. These include severe abdominal pain (potentially indicating pancreatitis), persistent vomiting leading to dehydration, or allergic reactions such as rash or difficulty breathing. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use Wegovy at any dose [7]. All prescriptions through Cured Pharmacy include a comprehensive clinical assessment by UK-registered prescribers to identify contraindications before treatment initiation.

When to Contact Your Prescriber About 0.25 mg Dosing

Contact your healthcare provider if you experience persistent side effects that interfere with daily activities, even at the 0.25 mg starting dose shown on the wegovy 0.25 click chart. Additionally, seek guidance if you miss more than two consecutive doses, as your prescriber may need to restart the titration schedule from 0.25 mg to minimise gastrointestinal distress. Our team at Cured Pharmacy remains available via phone at (+44) 116 4646009 for dosing questions and clinical support throughout your treatment journey.

Storage and Handling Guidelines for Wegovy 0.25 Click Chart Pens

Proper storage of Wegovy pens ensures medication efficacy throughout the treatment period covered by the wegovy 0.25 click chart. Unopened pens must be refrigerated at 2-8°C and protected from light until first use. Once in use, pens may be stored at room temperature (up to 30°C) for up to 28 days, making them convenient for patients who travel or prefer not to refrigerate medication constantly [8]. Never freeze Wegovy pens, and discard any that have been frozen, as this permanently damages the medication.

Each pen is designed for single-patient use only and should never be shared, even if the needle is changed. After completing your 0.25 mg dose, replace the pen cap and store the device in a safe location away from direct heat and sunlight. Dispose of used needles immediately in a sharps container approved for medical waste, and return used pens to a pharmacy for proper disposal once the 28-day use period expires or the medication is depleted. These handling practices, emphasised in the wegovy 0.25 click chart instructions, prevent contamination and ensure patient safety.

Accessing Wegovy 0.25 Click Chart Treatment Through Cured Pharmacy

Patients seeking wegovy 0.25 click chart guidance and Wegovy prescriptions can access treatment through Cured Pharmacy's streamlined online consultation service. Our UK-registered clinical team provides free assessments that typically take under three minutes, evaluating medical history, current medications, and weight loss goals to determine suitability for Wegovy therapy. Wegovy is available from £69.00, with £20 off your first order using code Weightlossnew, representing competitive UK pricing for this MHRA-licensed medication.

All Wegovy prescriptions include comprehensive dosing instructions, including the wegovy 0.25 click chart for starting doses, patient information leaflets, and direct access to our pharmacist team for ongoing support. As a GPhC-registered pharmacy (registration number 9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073), we supply only genuine UK-licensed medications with discreet packaging and fast delivery. Treatment requires clinical approval from our prescribers, ensuring safe and appropriate use for every patient.

Transparent Pricing and Clinical Support

At Cured Pharmacy, we display upfront pricing before consultation, eliminating hidden costs and ensuring patients understand their financial commitment. The wegovy 0.25 click chart is provided free with every prescription, alongside detailed injection technique videos and written guides. Our clinical team remains available throughout your treatment for dose adjustment queries, side effect management, and general support, ensuring optimal outcomes from your Wegovy therapy.

Scientific References

1. Novo Nordisk. (2023). Wegovy (semaglutide) injection prescribing information. Novo Nordisk A/S. [accessed 11 September 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 11 September 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen: Patient information leaflet. MHRA. [accessed 11 September 2026]
4. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 11 September 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 11 September 2026]
6. Kushner, R. F., Calanna, S., Davies, M., et al. (2020). Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5. Obesity, 28(6), 1050-1061. [accessed 11 September 2026]
7. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 11 September 2026]
8. European Medicines Agency. (2022). Wegovy: EPAR - Product information. EMA. [accessed 11 September 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 11 September 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 11 September 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 11 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.